Biggest Losers (MNTA) (DKS) (AAP) (VFC) (MFN) on May 6

Among the big, negative movers on Friday, May 6, were Momenta Pharmaceuticals (MNTA), Dick's Sporting Goods (DKS), Advance Auto Parts (AAP), V.F. Corp. (VFC) and Minefinders Corp. (MFN).

Momenta Pharmaceuticals (MNTA) was down $0.82, to close at $17.43, a loss of 4.49 percent.

Dick's Sporting Goods (DKS) fell $0.81 on the day to close at $40.01, a loss of 1.98 percent.

Advance Auto Parts (AAP) dropped $0.81 to close at $65.05, a loss of 1.23 percent.

V.F. Corp. (VFC) declined $0.81 to close the session at $99.73, a loss of 0.81 percent.

Minefinders Corp. (MFN) plunged $0.81 to end the day at $13.14, a loss of 5.81 percent.

Buy Momenta Pharmaceuticals (NASDAQ:MNTA) on Weakness Advises Canaccord

Citing several catalysts and factor surrounding Momenta Pharmaceuticals (NASDAQ:MNTA), Canaccord see mostly positives for the company, and recommends buying them on weakness.

Canaccord says, "We think m-enoxaparin’s (MNTA/Sandoz generic Lovenox) sales are robust but Teva’s generic enox may be out mid-2011. We think M356, MNTA/Sandoz’ generic Copaxone, is approvable without large clinical trials and MNTA will get positive clarity in the patent suit in H2/11. Our $27 target is based on a sum of the parts analysis."

Canaccord Genuity maintains a "Buy" on Momenta Pharmaceuticals (MNTA), which closed Wednesday at $13.26, up $0.76, or 6.08 percent. Canaccord has a price target of $27 on Momenta.

Momenta Pharmaceuticals (NASDAQ:MNTA) Driven by M356 Potential

Based on the potential of M356, Canaccord continues to be positive on Momenta Pharmaceuticals (NASDAQ:MNTA), with the high probability of it being approved with minimal trials.

Canaccord says, "Reiterate BUY, price target, and thesis based on M356 potential, technology platform - We think launch of m-enoxaparin (Momenta/Sandoz’ generic Lovenox) is going well but that Teva’s (Nasdaq:TEVA) generic enox may be out H1/11. We think M356, Momenta/Sandoz’ generic of Copaxone, is approvable without large clinical trials and MNTA will get positive clarity in the M356 patent suit in 2011. Our PT target is based on a sum of the parts analysis."

Canaccord Genuity maintains a "Buy" rating on Momenta Pharmaceuticals (MNTA), which closed Monday at $15.80, up $0.65, or 4.29 percent. Canaccord has a price target of $27 on them.